-
公开(公告)号：US20240101669A1
公开(公告)日：2024-03-28
申请号：US18448870
申请日：2023-08-11
申请人： Compugen Ltd.
发明人： Mark White , Sandeep Kumar , Christopher Chan , Spencer Liang , Lance Stapleton , Andrew W. Drake , Yosi Gozlan , Ilan Vaknin , Shirley Sameah-Greenwald , Liat Dassa , Zohar Tiran , Gad S. Cojocaru , Leonard Presta , Richard Theolis
IPC分类号： C07K16/28 , C07K7/06 , G01N33/574
CPC分类号： C07K16/2803 , C07K7/06 , G01N33/57484 , C07K2317/33 , C07K2317/70 , C07K2317/74 , C07K2319/30 , C07K2319/32 , C12N15/1138
摘要： The present invention is directed to anti-PVRIG antibodies and methods of using same.
-
公开(公告)号：US20240082397A1
公开(公告)日：2024-03-14
申请号：US18263171
申请日：2022-01-28
申请人： COMPUGEN LTD.
发明人： Mark WHITE , Inbal BARBIRO , Ilan VAKNIN , Assaf WOOL , Zurit LEVINE , Henry Adeboye ADEWOYE, MD , Michael BUCKLEY , Jun LU , John HUNTER , Anat COHEN-DAYAG , Gad S. COJOCARU , Eran OPHIR , Zoya ALTEBER
CPC分类号： A61K39/39591 , A61K47/02 , A61K47/183 , A61K47/22 , A61K47/26 , A61P35/00 , C07K16/28 , A61K2039/505
摘要： The present invention is directed to anti-PVRIG antibodies and stable liquid pharmaceutical formulations thereof. The present invention is directed to monotherapy and combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.
-
公开(公告)号：US20240075137A1
公开(公告)日：2024-03-07
申请号：US18322545
申请日：2023-05-23
申请人： Compugen Ltd.
发明人： Mark White , Sandeep Kumar , Christopher Chan , Spencer Liang , Lance Stapleton , Andrew W. Drake , Yosi Gozlan , Ilan Vaknin , Shirley Sameah-Greenwald , Liat Dassa , Zohar Tiran , Gad S. Cojocaru , Maya Kotturi , Hsin-Yuan Cheng , Kyle Hansen , David Nisim Giladi , Einav Safyon , Eran Ophir , Leonard Presta , Richard Theolis , Radhika Desai , Patrick Wall
IPC分类号： A61K39/395 , A61P35/00 , C07K16/28
CPC分类号： A61K39/39558 , A61K39/39541 , A61P35/00 , C07K16/2803 , C07K16/2809 , C07K16/2818 , C07K16/2827 , A61K2039/505
摘要： Anti-PVRIG and anti-TIGIT antibodies are provided.
-
公开(公告)号：US11795220B2
公开(公告)日：2023-10-24
申请号：US16904510
申请日：2020-06-17
申请人： Compugen Ltd.
发明人： Mark White , Sandeep Kumar , Christopher Chan , Spencer Liang , Lance Stapleton , Andrew W. Drake , Yosi Gozlan , Ilan Vaknin , Shirley Sameah-Greenwald , Liat Dassa , Zohar Tiran , Gad S. Cojocaru , Leonard Presta , Richard Theolis
IPC分类号： C07K16/28 , C07K7/06 , G01N33/574 , C12N15/113
CPC分类号： C07K16/2803 , C07K7/06 , G01N33/57484 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/53 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/70 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C07K2319/30 , C07K2319/32 , C12N15/1138 , C12N2310/14 , G01N2333/47
摘要： The present invention is directed to anti-PVRIG antibodies and methods of using same.
-
公开(公告)号：US11623955B2
公开(公告)日：2023-04-11
申请号：US16748695
申请日：2020-01-21
申请人： Compugen Ltd.
发明人： Mark White , Sandeep Kumar , Christopher Chan , Spencer Liang , Lance Stapleton , Andrew W. Drake , Yosi Gozlan , Ilan Vaknin , Shirley Sameah-Greenwald , Liat Dassa , Zohar Tiran , Gad S. Cojocaru , Leonard Presta , Richard Theolis
IPC分类号： C07K16/28 , C07K7/06 , G01N33/574 , C12N15/113
摘要： The present invention is directed to anti-PVRIG antibodies and methods of using same.
-
公开(公告)号：US10751415B2
公开(公告)日：2020-08-25
申请号：US15680187
申请日：2017-08-17
申请人： Compugen Ltd.
发明人： Mark White , Sandeep Kumar , Christopher Chan , Spencer Liang , Lance Stapleton , Andrew W. Drake , Yosi Gozlan , Ilan Vaknin , Shirley Sameah-Greenwald , Liat Dassa , Zohar Tiran , Gad S. Cojocaru , Maya Kotturi , Hsin-Yuan Cheng , Kyle Hansen , David Nisim Giladi , Einav Safyon , Eran Ophir , Leonard Presta , Richard Theolis , Radhika Desai , Patrick Wall
IPC分类号： C07K16/00 , A61K39/395 , C07K16/28 , A61P35/00 , A61K39/00
摘要： Anti-PVRIG and anti-TIGIT antibodies are provided.
-
公开(公告)号：US20190382477A1
公开(公告)日：2019-12-19
申请号：US16428856
申请日：2019-05-31
申请人： Compugen Ltd.
发明人： Andrew W. Drake , Sandeep Kumar , Sayantan Mitra , Adam Sallers , Sarah Whelan , Arun Kashyap , Keith Akama , Neha Yevaekar
摘要： Anti-PVRIG, anti-TIGIT, and anti-PVRIG/anti-TIGIT bispecific antibodies are provided, as well as compositions, and methods of using the antibodies for the treatment of cancer.
-
8.发明申请公开(公告)号：US20170107284A1
公开(公告)日：2017-04-20
申请号：US15363986
申请日：2016-11-29
申请人： Compugen Ltd
发明人： Amir TOPORIK , Amit NOVIK , Anat COHEN-DAYAG , Avi Yeshah ROSENBERG , Eve MONTIA , Galit ROTMAN , Liat DASSA , Merav BEIMAN , Ofer LEVY , Shira WALACH , Shirley SAMEACH- GREENWALD , Yaron KINAR , Zurit LEVINE , Gad S. COJOCARU , Sergey NEMZER
IPC分类号： C07K16/28 , G01N33/577 , G01N33/574 , C07K16/30 , A61K39/395
CPC分类号： C07K16/28 , A61K38/00 , A61K39/39558 , A61K2039/505 , C07K14/47 , C07K16/30 , C07K16/3015 , C07K16/3038 , C07K16/3053 , C07K16/3061 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C12Q1/6886 , C12Q2600/136 , G01N33/57484 , G01N33/577 , G01N2333/47
摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KRTCAP3, FAM26F, MGC52498, FAM70A or TMEM154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages. This invention further relates to extracellular domains of KRTCAP3, FAM26F, MGC52498, FAM70A and TMEM154 proteins and variants, and therapeutic usages thereof.
-
9.发明申请VSTM5 POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASES 审中-公开VSTM5多肽及其作为治疗癌症，感染性疾病和免疫相关疾病的药物的用途公开(公告)号：US20160347814A1
公开(公告)日：2016-12-01
申请号：US15066905
申请日：2016-03-10
申请人： Compugen Ltd.
发明人： Zurit LEVINE , Galit ROTMAN , Liat DASSA , Ofer LEVY , Gad S. COJOCARU , Amir TOPORIK , Yossef KLIGER , Ilan VAKNIN , Iris HECHT
IPC分类号： C07K14/705 , A61K45/06 , G01N33/574 , A61K39/39
CPC分类号： C07K14/705 , A61K31/675 , A61K38/00 , A61K39/39 , A61K45/06 , C07K2319/00 , C07K2319/30 , C07K2319/31 , G01N33/564 , G01N33/569 , G01N33/574 , G01N33/57492 , G01N2333/4703 , G01N2333/705 , Y02A50/411 , Y02A50/423 , A61K2300/00
摘要： This invention relates to VSTM5 proteins, soluble molecules and fusions thereof which are suitable targets for drug development and for treatment of immune related disorders, immunotherapy, treatment of cancer, infectious disorders and/or sepsis.
摘要翻译： 本发明涉及VSTM5蛋白质，其可溶性分子及其融合物，其是用于药物开发和治疗免疫相关疾病，免疫治疗，癌症治疗，感染性疾病和/或败血症的合适靶标。
-
10.发明申请POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTION 审中-公开用于治疗自身免疫性疾病和感染的多肽及其用途公开(公告)号：US20160304579A1
公开(公告)日：2016-10-20
申请号：US15055960
申请日：2016-02-29
申请人： Compugen Ltd.
发明人： Amir TOPORIK , Avi Yeshah ROSENBERG , Galit ROTMAN , Iris HECHT , Zurit LEVINE
IPC分类号： C07K14/705 , C12N5/0783
CPC分类号： C07K14/70503 , A61K38/00 , A61K39/395 , A61K45/06 , C07K16/18 , C07K2319/30 , C07K2319/74 , C12N5/0636 , Y02A50/401
摘要： This invention relates to C1ORF32 protein and its variants and fragments and fusion proteins thereof, pharmaceutical composition comprising same and methods of use thereof for treatment of immune related disorders and infections.
摘要翻译： 本发明涉及C1ORF32蛋白及其变体及其片段和融合蛋白，包含其的药物组合物及其用于治疗免疫相关疾病和感染的方法。
-
-
-
-
-
-
-
-
-
搜索结果
87 条记录 (耗时 0.035 秒)
